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BACKGROUND: Relationships between clinical researchers and industry are becoming increasingly com-
plex. The frequency and impact of conflicts of interest in the full range of high-impact, published clinical
cancer research is unknown. METHODS: The authors reviewed cancer research published in 8 journals in
2006 to determine frequency of self-reported conflicts of interest, source of study funding, and other char-
acteristics. They assessed associations between the likelihood of conflicts of interest and other characteris-
tics by using chi-squared testing. They also compared the likelihood of positive outcome in randomized
trials with and without conflicts of interest by chi-squared testing. RESULTS: The authors identified 1534
original oncology studies; 29% had conflicts of interest (including industrial funding) and 17% declared
industrial funding. Conflicts of interest varied by discipline (P < .001), continental origin (P < .001), and sex
(P < .001) of the corresponding author and were most likely in articles with corresponding authors from
departments of medical oncology (45%), those from North America (33%), and those with male first and
senior authors (37%). Frequency of conflicts also varied considerably depending upon disease site studied.
Studies with industrial funding were more likely to focus on treatment (62% vs 36%; P < .001), and random-
ized trials that assessed survival were more likely to report positive survival outcomes when a conflict of in-
terest was present (P ¼ .04). CONCLUSIONS: Conflicts of interest characterize a substantial minority of
clinical cancer research published in high-impact journals. Therefore, attempts to disentangle the cancer
research effort from industry merit further attention, and journals should embrace both rigorous standards
of disclosure and heightened scrutiny when conflicts exist. Cancer 2009;115:2783–91. VC 2009 American
Cancer Society.
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In recent years, relationships between clinical researchers and industry have become increasingly complex.
Researchers may not only rely upon industry for study funding1,2 but may also receive consulting fees,
own stock, and hold leadership positions within organizations that profit from selling the very drugs and
devices that are the subjects of researchers’ investigations.3,4
Several studies have suggested that industry-sponsored studies tend to reach conclusions favorable to
the sponsor5-16 and to use study designs more likely to favor the sponsored intervention than studies
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without industrial sponsorship.8,13,16,17 Studies have also
indicated that ties to industry may influence the nature,
focus, and dissemination of research undertaken by
researchers with those ties.1,2,18 Concerned by these find-
ings, medical journals have increasingly implemented pol-
icies that require researchers to disclose potential conflicts
of interest.19-21
Although previous studies have sought to define the
frequency of conflicts of interest among scientific and
medical researchers, many of these estimates are already
dated, and few have focused upon cancer research specifi-
cally. A recent study found that the majority of clinical tri-
als of systemic anticancer and supportive care drugs
reported in the Journal of Clinical Oncology in 2005
declared conflicts of interest.22 Yet the broader epidemiol-
ogy of conflicts of interest in current, published oncology
literature remains unexplored. It is quite possible that
studies considering diagnostic tests, technologies, and sur-
gical interventions may differ substantially from trials of
pharmacologic agents. Therefore, the impact of the
‘‘industrialization of clinical research’’ upon the field of
oncology merits further attention.23 This is particularly
important in light of changes in political priorities that
made the competition for scarce federal research funds
increasingly intense, potentially fueling an even greater
reliance upon private sources in recent years.
Therefore, in this study, we sought to characterize in
greater detail the sources of funding for the clinical cancer
research recently published in high-impact medical jour-
nals, to examine the frequency and nature of conflicts of
interest declared, and to consider possible associations
between conflicts of interest and investigator characteris-
tics, disease site, study focus, and study outcome.
MATERIALS AND METHODS
Inclusion Criteria
This study focuses upon research published in 2006 in
selected, high-impact, English-language journals. Journals
were selected after consideration of journal impact factors,
citation half-life, and readership. Only journals that pri-
marily publish original, clinical oncology research were
included; journals that focus upon reviews or basic science
investigation alone were excluded. Three journals cata-
logued by the Thomson ISI Journal Citation Index as gen-
eral medical journals were included as follows: the New
England Journal of Medicine, JAMA, the Journal of the
American Medical Association, and the Lancet. Five jour-
nals catalogued as oncology journals were included: the
Journal of Clinical Oncology, the Journal of the National
Cancer Institute, the Lancet Oncology, Clinical Cancer
Research, and Cancer. All articles listed as original investi-
gations were reviewed (in Clinical Cancer Research, only
articles under the subheading ‘‘Cancer Therapy: Clinical’’
were included); special articles, editorials, and review
articles were excluded. Original investigations that were
published in the general medical journals were reviewed
to determine whether their subjects were oncology.
Coding
All original oncology articles identified in this manner
were then analyzed to determine certain objective attrib-
utes: cancer type and/or site, declared source(s) of funding
and conflicts of interest, author affiliations, and sex of the
primary and senior (final) authors. The sex of the author
was determined by inspection of the author’s name; for
names in which sex was ambiguous, internet searches were
used in an attempt to determine sex, as described else-
where.24 The articles were also subjectively coded for
study type (prospective clinical vs other) and focus of
research (epidemiology, prevention, risk factors for inci-
dence, screening, or diagnostic methods; treatment with
curative intent, or treatment with palliative intent).
Data were entered by 2 medical-student coders into
a Microsoft Access database (N.S. and S.A.; Microsoft,
Redmond, Wash). The senior investigator (R.J.) closely
supervised the coding process, including a personal review
of 100 articles coded by each of the 2 medical-student
coders to improve accuracy and consistency in the coding
process. In order further to ensure inter-rater reliability,
10% of the articles, distributed across all included jour-
nals, were assessed independently by both coders. All dis-
crepancies in this subset were analyzed further to
determine the nature and frequency of coding disagree-
ments for each item. Discrepancies were resolved by the
consensus of 2 additional individuals (A.M. and R.J.),
and overall error rates for each item were thus determined.
For all objective attributes assessed, error rates were less
than 5%. For the coding categories on study type and
focus, which required subjective assessment on the part of
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the coders, we formally assessed the level of interobserver
agreement. For classification of the study as a prospective
clinical oncology study versus other type of study, the 2
coders were found to agree in 89% of the cases in the over-
lapped sample. This corresponded to a kappa of 0.74, in-
dicative of good interobserver agreement.25 For the
classification of the major focus of the study as epidemiol-
ogy, prevention, risk factors for incidence, screening, or
diagnostic methods, the 2 coders agreed in 77% of cases,
with a kappa of 0.53, indicative of fair interobserver agree-
ment. For the classification of the major focus of the study
as treatment with curative intent, the 2 coders agreed in
84% of cases, with a kappa of 0.63, indicative of good
interobserver agreement. For the classification of the
major focus of the study as treatment with palliative
intent, the 2 coders agreed in 99% of cases. Given the
infrequency of this classification, kappa is an inappropri-
ate measure of interobserver agreement and was not
calculated.
All randomized clinical trials were further exam-
ined to assess the authors’ subjective interpretation of
outcome, and for studies in which overall survival was
assessed, to determine an objective measure of outcome
based upon the statistical significance of survival impact.
The randomized studies identified in the initial coding
phase were printed for subsequent blinded coding of
outcomes. Sections containing author names and affilia-
tions were blacked out, and all articles were physically
cut after the last sentence of the conclusions to blind
reviewers as to whether a conflict of interest disclosure
was made. All randomized trials were coded for out-
comes by 2 blinded coders who had not reviewed the
papers in the initial coding phase. Authors’ subjective
interpretations were graded qualitatively as positive (pre-
senting the intervention arm as preferable to the control
arm), neutral, or negative (presenting the control arm as
preferable to the intervention arm). Overall survival was
assessed quantitatively, with a positive result defined as a
significant (P < .05) survival difference in favor of the
intervention, positive trend (P  .10) toward signifi-
cance in favor of the intervention, neutral as no signifi-
cant difference between the 2 arms, negative trend (P 
.10) toward significance in favor of the control arm, and
negative as a significant (P < .05) survival difference in
favor of the control arm. Discrepancies between the 2
blinded coders were resolved by blinded consensus.
Analysis
For the purposes of analysis, a conflict of interest was
defined to be present when a conflict of interest was ex-
plicitly declared by the authors, when an author was an
employee of industry at the time of publication, or when
the study reported industry as the funding source. Statisti-
cal analysis was performed by using SPSS version 14.0
software (SPSS, Chicago, Ill). Chi-squared testing was
used to determine the significance of associations between
industrial funding or conflict of interest and disease site,
author characteristics, and study type and focus. Because
all applicable articles published in the selected journals
during the chosen year were reviewed, the cases in our
database constitute the entire universe of applicable data
points; therefore, these estimates are exact and contain no
statistical uncertainty.
RESULTS
We identified 2701 original articles published in the
selected journals in the year 2006, of which 1534 were
oncology studies.
Table 1 details the sources of funding and frequency
of conflicts of interest declared in the research articles
studied, by journal. Overall, 29% of the papers had con-
flicts of interest, and 17% declared industrial funding.
As shown in Figure 1, there was a statistically signifi-
cant difference in the proportion of studies that declared
industrial funding (P < .001) or that had any conflicts of
interest (P < .001) by study discipline, as defined by the
department of the corresponding author. Studies that had
a corresponding author from a medical oncology depart-
ment or division were most likely to have conflicts (45%),
and studies from diagnostic radiology were least likely to
have conflicts (4%).
Table 2 presents funding sources and frequency of
conflicts of interest by disease type and/or site studied,
revealing considerable variability in the frequency of con-
flicts of interest (P ¼ .02) and likelihood of industrial
funding (P¼ .001) between different cancer types and/or
sites.
There was also a statistically significant association
between geography and frequency of industrial funding
and conflicts of interest. Of the 965 studies with authors
based in North America, 19% declared industrial fund-
ing, compared with 17% of the 405 studies from Europe,
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2% of the 117 studies from Asia, and 21% of the 47 stud-
ies from elsewhere (P < .001). Conflicts of interest were
observed in 33% of the North American studies, 27% of
the European studies, 5% of the Asian studies, and 40%
of the studies from other locations (P< .001).
Sex of the first and senior authors was determined in
1505 articles. In these articles, 33% of the first authors
and 20% of the senior authors were female. Articles with a
woman as first or senior author were less likely to be
funded by industry (13% vs 23%; P < .001) or to have
conflicts of interest (24% vs 37%), but these articles were
more likely to have any source of funding declared (76%
vs 68%; P< .001), when compared with studies in which
both first and senior authors were men.
The types of conflicts of interest in the examined
articles are described in Figure 2. Most frequent was
industrial funding of the study (present in 17% of
articles), followed by participation in authorship by an
employee of industry (present in 12% of articles).
Among the 261 industry-funded studies, 62% had a
major focus upon treatment with curative intent. This was
significantly higher than the proportion among studies
not funded by industry (36%; P < .001). Few studies,
funded by industry or not, had a major focus upon treat-
ment with palliative intent, but the proportion of indus-
try-funded studies with this focus was higher than the
proportion of studies not reporting industrial funding
(5% vs 2%; P ¼ .002). Industry-funded studies were less
likely than those not declaring industrial funding to focus
upon epidemiology, prevention, risk factors for incidence,
screening, or diagnostic methods (20% vs 47%; P <
.001).
Of the 661 prospective clinical studies identified in
our dataset, 211 (32%) were industry-funded, and 312
(47%) had a conflict of interest. The majority (81%) of
the industry-funded studies were prospective clinical stud-
ies, whereas only 35% of studies that did not declare
industrial funding were prospective clinical studies (P <
.001).
Table 3 presents the results of the blinded outcomes
analysis of the 124 randomized trials identified in the
sample. Among studies that reported overall survival,
those studies with conflicts of interest were more likely to
have positive findings (P ¼ .04). There was no observed
difference in the likelihood that the author interpretation
was positive nor in the likelihood that the author interpre-
tation was more positive than the objective assessment of
effect on overall survival. No significant differences were
observed between studies reporting industrial funding
Table 1. Funding Sources and Conflicts of Interest in Original Cancer Research Publications Appearing in
















Overall 1534 29 17 50 29
Cancer 602 16 11 38 27
Clin Cancer Res 144 40 25 52 40
JAMA 27 44 19 78 22
JCO 565 39 23 50 30
JNCI 123 20 6 89 33
The Lancet 8 38 25 63 38
The Lancet Oncology 34 35 18 41 38
NEJM 31 61 39 77 10
FIGURE 1. This figure depicts the frequency of conflicts of in-
terest (including industrial funding) declared by articles with
corresponding authors from different departmental and divi-
sional affiliations.
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and those not reporting industrial funding for any of the
blinded outcomes assessed.
DISCUSSION
In this study, we have found that conflicts of interest char-
acterize a substantial minority of the clinically oriented
cancer research published in high-impact medical jour-
nals. Conflicts of interest were most likely in articles with
corresponding authors from departments of medical on-
cology, those from North America, and those with male
first and senior authors, and the frequency of conflicts var-
ied considerably depending upon disease site studied.
Articles that reported industrial funding were more likely
to have a focus on treatment than were studies that did
not report such funding, and randomized trials with a
conflict of interest were more likely to report positive sur-
vival outcomes.
Our work complements other studies that have
sought to illuminate the frequency, nature, and effects of
conflicts of interest in modern clinical oncology research.
Hampson and colleagues recently examined the conflict
of interest disclosure forms submitted by authors of
abstracts presented at the 2004 and 2005 annual meetings
of the American Society of Clinical Oncology.26 They
found that 23.8% of the abstracts in 2004 and 17.0% in
2005 disclosed research funding, and 23% of the abstracts
in those 2 years had at least 1 author who disclosed a per-
sonal financial interest. They also found that almost 20%
of abstracts had at least 1 author who was employed by or
played a leadership role in a commercial entity. Our find-
ings provide a complementary perspective on these
important issues. After all, although certain abstracts—
particularly those presented in plenary sessions—may be
quite influential, abstracts are primarily intended to pres-
ent preliminary findings and do not always result in peer-
reviewed publications, which are the primary means by
which research findings influence practice.27 Therefore, it
is useful also to consider the sources of funding and nature
of conflicts disclosed in the clinical studies that have
achieved publication in high-impact journals.28 Our find-
ings that 12% of articles had authors who were employees
of industry and that 17%were funded by industry provide
a useful complement to the insights yielded by the work
of Hampson et al.
Other researchers have previously examined the
published cancer-research literature for conflicts of inter-
est and funding sources. Tuech and colleagues29 charac-
terized the sources of sponsorship and competing
financial interests disclosed in 655 cancer randomized tri-
als published from 1999-2003 in 12 international
















Overall 1534 24 17 50 29
Breast 263 29 16 55 35
Hematologic 211 35 21 40 29
Gastrointestinal 214 29 16 54 30
Urinary 66 27 18 35 18
Prostate, testis, penis 128 35 23 58 30
Lung 137 32 21 49 20
Nervous system 67 3 4 45 34
Gynecologic 83 20 6 61 28
Head and neck 72 18 11 47 33
Skin 60 33 18 58 28
Sarcoma 61 16 8 38 36
* Studies that considered several cancer types and/or sites are included in each major type and/or site category that these studies considered.
FIGURE 2. This figure depicts the frequency of different types
of conflict of interest declared in the articles analyzed.
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journals and found that 227 trials disclosed industrial
funding. Riechelmann and colleagues examined conflicts
of interests disclosed in 289 clinical trials and 43 editorials
that considered systemic anticancer agents and support-
ive-care drugs published in the Journal of Clinical Oncol-
ogy in 2005 and found conflicts in 69% of the trials.22
The higher rates of conflicts observed in those studies are
consistent with the observation in the current study that
prospective studies and studies conducted by medical
oncologists are more likely to have conflicts of interest.
Our study, thus, complements those studies by consider-
ing a larger selection of study types in more detailed fash-
ion (including a differentiation between governmental
and private philanthropic funders) in a more recent year,
as well as by analyzing the distribution of funding sources
by disease site and author sex.
Finally, the current study adds to the literature that
has explored correlations between industrial funding and
positive study outcome. Several previous studies have
examined the relation between funding sources and out-
comes of published clinical trials. These prior studies
include a seminal analysis of 107 controlled clinical trials,
which found that a substantially higher proportion of
studies favoring new therapies were funded by industry
than the proportion of studies favoring traditional thera-
pies that were funded by industry.6 Since then, several
other studies have explored this issue in greater
detail,5,7,8,16,30-34 including several that have focused
upon specific medical specialties, such as cardiology,35
psychiatry,36,37 gastroenterology,38 and orthopedics.13,39-41
In general, these studies have also found that industry-
funded studies are more likely to have positive study out-
comes than those conducted without industrial funding,
although some have failed to identify a relation between
funding source and trial outcome.42 Relatively little work
of this nature has explored the oncology literature. A small
but influential study examined 44 cost-effectiveness stud-
ies of new drugs in oncology, documenting that industry-
sponsored studies were less likely to report unfavorable
qualitative conclusions concerning the cost or cost effec-
tiveness of the drugs than nonprofit-sponsored stud-
ies.11,43 More recently, another study examined 150
health-economics studies within the field of oncology and
found that industry-sponsored studies were more likely to
be cost-minimization studies and more likely to draw pos-
itive qualitative conclusions about costs than those sup-
ported by nonprofit organizations.44 Another recent
study of breast-cancer clinical trials found that of 56 stud-
ies published in the year 2003, those that reported an
involvement with a pharmaceutical corporation were
more likely to report positive conclusions.45
Similarly, we find among the randomized trials that
assessed survival in our sample, those studies with conflicts
of interest were more likely to report positive outcomes.
However, because we did not find a higher rate of discord-
antly positive author interpretations of outcome in the







No. (%) with positive author interpretation of outcomes 29 (56) 48 (67) .22
No. (%) in which overall survival was assessed 36 (69) 51 (71) .85
Overall survival outcomes* .04
Positive (significantly favoring intervention) 5 (14) 15 (29)
Positive trend 1 (3) 4 (8)
Neutral 26 (72) 31 (61)
Negative trend 2 (6) 1 (1)
Negative (significantly favoring control) 2 (6) 0
No. (%) in which author interpretation was more positive than
supported by analysis of overall survival outcome aloney
15 (50) 16 (50) 1.00
* Positive defined as a significant (p<.05) survival difference in favor of the intervention; positive trend defined as a trend (p.10) toward significance in favor
of the intervention; neutral defined as no significant difference between the 2 arms; negative trend defined as a trend (p.10) toward significance in favor of
the control arm; negative defined as a significant survival difference in favor of the control arm.
yAuthor interpretation was deemed to be more positive than supported by analysis of overall survival alone when author interpretation was coded as positive
but overall survival outcome was neutral, negative trend, or negative, as well as when author interpretation was neutral and overall survival outcome was
negative trend or negative. Percentage is calculated from the total number of neutral, negative trend, and negative studies.
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studies with conflicts of interest, we do not believe that
the reason underlying this observed difference is simply
interpretation or a tendency for studies with conflicts of
interest to focus upon outcomes other than overall sur-
vival. Another potential mechanism is publication bias46;
author groups with conflicts of interest may be even more
likely to publish positive results (or less likely to publish
negative results) than others. These findings are also con-
sistent with the suggestion that studies supported by
industry are more likely to use study designs that are more
likely to yield positive results (such as trials with a placebo
rather than active controls).8,47
The primary limitation of this study is that our data
rely upon self-reports by authors of any relevant funding
sources and potential conflicts of interest. We did not vali-
date these self-reports by obtaining personal financial
information from the authors or by querying corporate
board membership or employee lists. Recent news reports
reveal that authors may not always openly disclose rele-
vant conflicts. Furthermore, we are able only to ascertain
the prevalence of those conflicts that were published, and
it is possible that some journals might not have published
all conflicts that were reported. This is most likely to lead
to some degree of underestimation of the prevalence of
these conflicts, although it is also possible that some
authors may over-report potential conflicts where none
exist. Some of the associations observed in the current
study may result from systematic differences in the likeli-
hood of disclosing conflicts of interest rather than differ-
ences in rates of actually existing conflicts, particularly in
the face of differing journal policies48-54 and differing cul-
tural norms. Another potential limitation arises from the
focus upon 8 high-impact journals, most of which are
published in the United States. Journals published in
other countries may differ meaningfully, and future stud-
ies should seek to characterize the frequency, nature, and
associations of conflicts of interest as reported in those
journals. Nevertheless, we believe this study to present 1
of the most complete and updated analyses of the fre-
quency, nature, and effects of conflicts of interest in clini-
cal cancer research in existing literature.
In summary, the current study suggests that a sub-
stantial minority of the broad range of modern, high-
impact, published, clinical cancer research is open to the
influence of conflicts of interest. Certain study character-
istics, including discipline, national origin, and author
sex, are correlated with the likelihood of conflict. The fre-
quency of conflicts varies by cancer site and/or type stud-
ied, and studies with conflicts of interest are more likely to
focus upon treatment rather than diagnosis and preven-
tion. Most disturbingly, it appears that cancer research
studies in which conflicts of interest are present are indeed
more likely to report positive outcomes. In light of these
findings, attempts to disentangle the cancer-research
effort from industry ties merit further attention, and med-
ical journals should be supported in embracing both rigor-
ous standards of disclosure and heightened scrutiny when
conflicts exist.
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